Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

Minkyu Jung, JaSeung Koo, Young Wha Moon, Byeongwoo Park, Seung Il Kim, Seho Park, Soo Hyun Lee, Soojung Hong, SunYoung Rha, Hyuncheol Chung, Joo Hang Kim, Joohyuk Sohn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4-15.5) and a higher HER2 AI (≥5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P = 0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81% vs. 40%, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.

Original languageEnglish
Article numbere45127
JournalPloS one
Volume7
Issue number9
DOIs
Publication statusPublished - 2012 Sep 20

Fingerprint

paclitaxel
epidermal growth factor
Tubulin
Paclitaxel
tubulin
Epidermal Growth Factor
Genes
Amplification
Polymorphism
polymorphism
therapeutics
Disease-Free Survival
genes
Biomarkers
biomarkers
Therapeutics
Immunoglobulin Fragments
immunoglobulin G
formalin
breast neoplasms

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Jung, Minkyu ; Koo, JaSeung ; Moon, Young Wha ; Park, Byeongwoo ; Kim, Seung Il ; Park, Seho ; Lee, Soo Hyun ; Hong, Soojung ; Rha, SunYoung ; Chung, Hyuncheol ; Kim, Joo Hang ; Sohn, Joohyuk. / Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. In: PloS one. 2012 ; Vol. 7, No. 9.
@article{03b3569101d84d4e8d022826d85669df,
title = "Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy",
abstract = "Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4-15.5) and a higher HER2 AI (≥5.0) was significantly correlated with better response rate (RR) (80{\%} vs. 42{\%}, P = 0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81{\%} vs. 40{\%}, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.",
author = "Minkyu Jung and JaSeung Koo and Moon, {Young Wha} and Byeongwoo Park and Kim, {Seung Il} and Seho Park and Lee, {Soo Hyun} and Soojung Hong and SunYoung Rha and Hyuncheol Chung and Kim, {Joo Hang} and Joohyuk Sohn",
year = "2012",
month = "9",
day = "20",
doi = "10.1371/journal.pone.0045127",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. / Jung, Minkyu; Koo, JaSeung; Moon, Young Wha; Park, Byeongwoo; Kim, Seung Il; Park, Seho; Lee, Soo Hyun; Hong, Soojung; Rha, SunYoung; Chung, Hyuncheol; Kim, Joo Hang; Sohn, Joohyuk.

In: PloS one, Vol. 7, No. 9, e45127, 20.09.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

AU - Jung, Minkyu

AU - Koo, JaSeung

AU - Moon, Young Wha

AU - Park, Byeongwoo

AU - Kim, Seung Il

AU - Park, Seho

AU - Lee, Soo Hyun

AU - Hong, Soojung

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - Kim, Joo Hang

AU - Sohn, Joohyuk

PY - 2012/9/20

Y1 - 2012/9/20

N2 - Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4-15.5) and a higher HER2 AI (≥5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P = 0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81% vs. 40%, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.

AB - Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4-15.5) and a higher HER2 AI (≥5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P = 0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81% vs. 40%, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.

UR - http://www.scopus.com/inward/record.url?scp=84866646922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866646922&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0045127

DO - 10.1371/journal.pone.0045127

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e45127

ER -